We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Consumers Playing a Greater Role in Postmarket Surveillance

Consumers Playing a Greater Role in Postmarket Surveillance

June 10, 2008

Consumers became the major source of adverse event reports to the FDA in 2006, replacing physicians.

In 1998, consumers reported 23,691 adverse events as compared with 48,314 physician reports. In 2006, however, that trend reversed. That year saw 127,475 consumer reports versus 113,444 physician reports, according to FDA data, which was posted last week on the agency’s website.

Consumers reported 174,216 adverse events in 2007 — 53,216 more than reported by physicians, according to the data.

Although the agency’s reported information has limitations, the increase in consumer-reported adverse events is significant and could indicate greater awareness of drug safety issues. For example, drug safety concerns with GlaxoSmithKline’s anti-diabetes medication Avandia (rosiglitazone maleate) were widely reported by the media last year. Merck’s market withdrawal of Vioxx (rofecoxib) in 2004 also was highly publicized.

One limitation in examining the data is that some adverse event submissions do not have the reporter listed on the form, or there are multiple reporters for one adverse event. For example, in 2007 there were 397,902 instances of an identifiable reporter for an adverse event. However, the FDA entered a total of 364,449 direct, 15-day and periodic reports into the adverse reporting system during that same year, a discrepancy of more than 30,000.

The FDA also posted adverse event report data from other healthcare professionals, which show that the role of pharmacists in reporting adverse events has diminished. While total adverse events entered into the agency’s reporting system more than tripled from 106,384 in 1998 to 376,902 in 2007, pharmacist reports only increased from 18,193 to 21,343 during that same time frame.

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing